trending Market Intelligence /marketintelligence/en/news-insights/trending/hcffqoipqb2yxmurzdectg2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Fennec's ear damage prevention drug gets US FDA fast track status

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Fennec's ear damage prevention drug gets US FDA fast track status

The U.S. Food and Drug Administration granted the fast-track designation to Fennec Pharmaceuticals Inc.'s Pedmark to prevent ototoxicity, or ear damage, as a side-effect of cisplatin chemotherapy in children with standard-risk hepatoblastoma.

Hepatoblastoma is a very rare cancerous tumor that starts in the liver and primarily affects children.

The fast track designation allows the FDA to accelerate the review process for drugs indicated to treat serious and life-threatening conditions.